91
Participants
Start Date
March 7, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Treprostinil Palmitil
Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
Placebo
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
BEL003, Brussels
AUT001, Vienna
PHL001, Quezon City
PHL002, Makati City
AUT002, Linz
MYS005, Alor Star
DNK001, Aarhus
USA102, New York
SRB001, Belgrade
SRB003, Belgrade
MEX003, Mexico City
ITA005, Monza
GER002, Lübeck
MYS002, Kuantan
ITA002, Pavia
USA005, Jacksonville
USA011, Tampa
ESP001, Santander
ESP003, Seville
MEX005, Lomas de Guevara
MYS004, Sungai Buloh
USA006, Chicago
USA001, Chicago
MEX001, Monterrey
GER005, Heidelberg
USA016, Dallas
MEX004, San Luis Potosí City
GER003, München
ITA001, Palermo
ARG009, Quilmes
ARG006, Rosario
ARG007, San Miguel de Tucumán
ARG004, Córdoba
ARG001, Córdoba
BRA004, Belo Horizonte
BRA006, Porto Alegre
BRA002, Blumenau
ITA004, Roma
JPN005, Sapporo
JPN004, Sapporo
JPN007, Kurume-shi
JPN006, Tsukuba
JPN002, Okayama
JPN003, Suita-Shi
GBR001, Bath
Insmed Incorporated
INDUSTRY